Literature DB >> 29669139

Diuretic or sodium-restricted diet for obstructive sleep apnea-a randomized trial.

Cintia Zappe Fiori1,2, Denis Martinez1,2,3,4, Carolina Caruccio Montanari2,3, Pedro Lopez2,5, Rodrigo Camargo2, Lauren Sezerá2, Sandro Cadaval Gonçalves1,4, Flavio Danni Fuchs1,4.   

Abstract

Study
Objectives: Interventions that decrease leg fluid retention reduce obstructive sleep apnea (OSA) severity in nonrandomized experiments. We aimed to investigate in a randomized trial the effect of interventions that reduce fluid volume on OSA severity.
Methods: Men diagnosed with severe OSA were randomized to receive daily spironolactone 100 mg + furosemide 20 mg or nutritional counseling to sodium-restricted diet plus placebo pill or placebo pill. All participants underwent home sleep apnea testing at baseline and after 1 week follow-up. The change in apnea-hypopnea index (AHI) was the primary outcome.
Results: The study included 54 participants and all were assessed at follow-up. The average baseline value of the AHI was similar among groups and from baseline to follow-up the AHI reduced 14.4 per cent (δ value -7.3 events per hour; 95% confidence interval, -13.8 to -0.9) in the diuretic group, 22.3 per cent (-10.7; 95% CI, -15.6 to -5.7) in the diet group, and 0.8 per cent (0.4; 95% CI, -2.5 to 3.2) in the placebo group (p = .001 for time × group interaction). None of the patients had their AHI returned to normal. The reduction in the total body water was 2.2 ± 2.2 L in the diuretic group (p < .001) and 1.0 ± 1.6 l in the low salt diet group (p = .002). Sleepiness and neck circumference were significantly reduced only in the diet group (p = .007 and p < .001 for the time × group interactions, respectively). Conclusions: Interventions to reduce bodily fluid content in men with severe OSA promoted a limited decrease of apnea frequency. This finding suggests that rostral fluid displacement affects only partially the OSA severity and/or that other factors prevail in determining pharyngeal collapsibility. Clinical Trial: Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea (DESALT), https://clinicaltrials.gov/ct2/show/NCT01945801 ClinicalTrials.gov number: NCT01945801.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29669139     DOI: 10.1093/sleep/zsy016

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  7 in total

Review 1.  Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges.

Authors:  Grace Oscullo; Gerard Torres; Francisco Campos-Rodriguez; Tomás Posadas; Angela Reina-González; Esther Sapiña-Beltrán; Ferrán Barbé; Miguel Angel Martinez-Garcia
Journal:  J Clin Med       Date:  2019-11-05       Impact factor: 4.241

Review 2.  Targeting Endotypic Traits with Medications for the Pharmacological Treatment of Obstructive Sleep Apnea. A Review of the Current Literature.

Authors:  Luigi Taranto-Montemurro; Ludovico Messineo; Andrew Wellman
Journal:  J Clin Med       Date:  2019-11-02       Impact factor: 4.241

3.  To Salt or Not to Salt? Is That a Question in Obstructive Sleep Apnea?

Authors:  Takatoshi Kasai; Yüksel Peker
Journal:  Ann Am Thorac Soc       Date:  2021-03

4.  Effect of acetazolamide on obstructive sleep apnoea in highlanders: protocol for a randomised, placebo-controlled, double-blinded crossover trial.

Authors:  Lu Tan; Michael Furian; Taomei Li; Xiangdong Tang
Journal:  BMJ Open       Date:  2022-03-07       Impact factor: 2.692

Review 5.  Obstructive Sleep Apnea as a Cardiovascular Risk Factor-Beyond CPAP.

Authors:  Joshua M Bock; Soumya Vungarala; Shahid Karim; Virend K Somers
Journal:  Can J Cardiol       Date:  2021-02-19       Impact factor: 5.223

6.  Reply: Salt, Diuretics, and Obstructive Sleep Apnea.

Authors:  Soraya Giatti; Luciano F Drager
Journal:  Ann Am Thorac Soc       Date:  2021-12

7.  Diuretics in Patients with Obstructive Sleep Apnea and Concomitant Hypertension.

Authors:  Bruno Revol; Monique Mendelson; Sébastien Bailly; Renaud Tamisier; Marie Joyeux-Faure; Jean-Louis Pépin
Journal:  Ann Am Thorac Soc       Date:  2021-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.